My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

115.35 -3.89 (-3.26%)

Streaming Delayed Price Updated: 12:08 PM EDT, Jul 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Kymera (KYMR) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Analysts Have This To Say About Kymera Therapeutics ↗

November 05, 2025

Via Benzinga

Kymera Therapeutics Inc (NASDAQ:KYMR) Q3 2025 Earnings: Clinical Progress Overshadows Financial Miss ↗

November 04, 2025

Kymera Therapeutics stock rises on positive clinical updates for its atopic dermatitis drug, KT-621, despite missing Q3 2025 revenue and EPS estimates.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts ↗

October 17, 2025

Via Benzinga

Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views ↗

September 16, 2025

Via Benzinga

What to Expect from Kymera Therapeutics's Earnings ↗

August 08, 2025

Via Benzinga

What 6 Analyst Ratings Have To Say About Kymera Therapeutics ↗

June 03, 2025

Via Benzinga

This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

September 16, 2025

Via Benzinga

Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market ↗

August 11, 2025

Kymera Therapeutics Q2 2025 earnings miss estimates with $11.48M revenue (-55% YoY) and $0.95 EPS loss. Stock drops 2.7% pre-market despite clinical progress in STAT6 candidate.

Via Chartmill

Topics Earnings

Kymera Revenue Drops 55 Percent in Q2 ↗

August 11, 2025

Via The Motley Fool

Topics Intellectual Property

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' ↗

July 09, 2025

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock ↗

June 26, 2025

Via Benzinga

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗

June 26, 2025

Via Benzinga

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit ↗

June 25, 2025

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.

Via Stocktwits

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗

June 25, 2025

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Via Benzinga

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

June 25, 2025

From Gilead Sciences, Inc.

Via Business Wire

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

June 12, 2025

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

Via MarketBeat

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday ↗

June 03, 2025

Via Benzinga

Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 03, 2025

Via Benzinga

Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish ↗

June 02, 2025

Morgan Stanley, BofA, and Citi upgraded the stock, citing strong safety, biomarker, and degradation data for its STAT6 degrader KT-621.

Via Stocktwits

Here are the top movers in Monday's session. ↗

June 02, 2025

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Which stocks are experiencing notable movement on Monday? ↗

June 02, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗

June 02, 2025

Via Benzinga

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response ↗

June 02, 2025

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Via Benzinga

These stocks that are showing activity before the opening bell on Monday. ↗

June 02, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 30, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.